For patients with immunoglobulin G (IgG)4-related disease, inebilizumab reduces the risk for flares and increases the ...

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for ...

Over 2 decades ago, the aldosterone antagonist eplerenone proved beneficial after MI complicated by left ventricular ...

Attend Pittcon 2025 in Boston to connect with global leaders in laboratory science and explore cutting-edge advancements in ...

John held several financial positions of increasing responsibility, including Vice President of Finance and Administration ...

The S&P 500, Nasdaq and Dow all fell for the week, while pharmaceutical stocks slid after Trump picked anti-vaccine activist ...

The company said Tuesday that Dr. Cherry Thomas, formerly CMO of Boston-based Catamaran Bio ... Bristol-Myers Squibb, Beigene ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

Adding an anthracycline to adjuvant chemotherapy for TOP2A-normal early breast cancer significantly improved disease-free survival (DFS) but not overall survival (OS) at 10 years, and doubled the risk ...

--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor and Analyst Day in Boston on Tuesday ... leading biopharmaceutical companies ...